Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

The demand for weight loss drugs like Ozempic and Wegovy has led to a flood of fake drugs hitting the market. However, these ...

The majority of strokes could be prevented, according to new guidelines aimed at helping people and their doctors do just ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

A flood of dangerous counterfeit drugs is pouring into the U.S., including deadly fake versions of popular weight-loss drugs ...

Ozempic (semaglutide) is a well-known prescription drug that’s used to treat blood sugar of people with type 2 diabetes, has ...

Losing weight on GLP-1 drugs like Ozempic isn't guaranteed. Experts reveal how to tell if yours isn't working and the next steps you should take to reach your weight loss goals.

Slickly designed websites. Unbelievable markdowns. A simple online search for semaglutide, the active ingredient in Ozempic or Wegovy, can lead consumers down a rabbit hole of seemingly reputable ...

Since Eli Lilly's Mounjaro and Novo Nordisk's Wegovy and Ozempic fell into shortage in late 2022, compounding pharmacies have been manufacturing their respective generics, tirzepatide and semaglutide.